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Screening for Microalbuminuria in Type 
2 Diabetic Patients: the Evaluation of a 
Dipstick Test in General Practice
W.J.C. de Grauwa, E.H. van de Lisdonk3, H.J.M. van den Hoogen3, W.H.E.M. van Gerwen3,
W.J.H.M. van den Bosch*, J.L. Willemsb, C. van Weela
aDepartment o f General Practice and Social Medicine, University of 
Nijmegen, and bDepartment o f ClinicaI Chemistry, University 
Hospital, University o f Nijmegen, the Netherlands
To evaluate the Micral test, a semiquantitative dipstick test, in a general practice setting, 
317 Type 2 diabetic patients completed a screening for microalbuminuria by means of 
the Micral test as well as immuno-nephelometry with the Disc 120 immuno-nephelometer 
(Hyland, Nivelles, Belgium). Data were collected in 10 general practices performing the 
Nijmegen Monitoring Project At a regular check-up each Type 2 diabetic patient was 
asked to collect first morning urine samples on three consecutive days. The sensitivity of 
the Micral test was 67 %, the specificity 93 %. Between the practices the sensitivity 
ranged from 58 % to 81 %, the specificity from 87 % to 95 %. Microalbuminuria, defined 
as a mean urine albumin concentration >  20 mg I"1 by nephelometry on three consecutive 
days, was found in 66 patients (21 %). The first Micral test correctly picked out these 
patients with microalbuminuria in 70 % of the cases and in 90 % those patients without 
microalbuminuria. The diagnostic performance of the Micral test was further proved by 
a Receiver Operating Characteristic (ROC) curve. The Area Under the Curve (AUC) of 
the Micral test was 0.84 (95 % Cl 0.78-0.90)* Micral test results of 0 and 10 should be 
regarded as negative.
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Introduction
Microalbuminuria is defined as an albumin excretion 
rate (AER) of 20-200 jug min-1 in an overnight collection, 
or 30-300 mg 24 h“ 1.1 It is thought to be related to a 
number of risk factors for cardiovascular disease2~5and 
predicts the development of clinical proteinuria, early 
cardiovascular mortality,6“10 proliferative retinopathy,11 
and nephropathy.6 Although only 3-8% of the Type 
2 patients with nephropathy develop end-stage renal 
disease,12 the prevalence of this type of diabetes turns 
renal failure into a quantitative relevant problem. Approxi­
mately 50% of all diabetes patients requiring dialysis or 
transplantion therapy are Type 2 diabetes patients.13'14 
It is obvious that renal replacement therapy negatively 
influences patients health, quality of life, and economic 
aspects. Antihypertensive treatment will at least slow 
down the progression from microalbuminuria to persistent 
proteinuria.15' 17 The rate at which albumin excretion 
increases is related to long-term glycaemic control.10 
However, it remains to be established whether antihyper­
tensive treatment or strict blood glucose control will 
reduce the development of renal failure and cardiovascu­
lar morbidity and mortality. Moreover, the potential
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benefits of any screening and intervention have to be 
weighted against the costs of screening and treatment.
Although early disease detection and treatment seems 
simple, in practice many prerequisites have to be 
fulfilled.19 Gilbert recently reviewed the prognostic and 
therapeutic implications of microalbuminuria in diabetes 
meilitus,20 In agreement with former recommendations 
he concluded that screening for microalbuminuria seems 
justified.21,22 Moreover, he addressed the fact that screen­
ing helps to identify patients at high risk for retinopathy 
and cardiovascular diseases.20 Such patients in particular 
may benefit from more frequent and tight control.20
As most Type 2 diabetic patients are treated in general 
practice, an instrument to screen for microalbuminuria 
should be feasible in general practice. For this reason 
the collection of 24-h or timed samples is inconvenient, 
especially when repeated measures are proposed. More­
over, an albumin concentration in a first morning urine 
sample of 20 mg I"1 is a reasonable initial screening cut-off 
pointfor identifying patients with microalbuminuria*1,23“27 
Recently a cheap and simple to handle dipstick test for 
microalbuminuria (Micral test) was evaluated in a clinical 
setting. In the hands of trained laboratory technicians 
the following were found: a sensitivity of 75-100%, a 
specificity of 80-97 % compared to radioimmunoas­
say,28“33 a predictive value of a positive test result of 
55-72 % and of a negative test result of 97 %.33'34 The 
critical time of contact between stick and urine and 
reading may be a major source of error in the use of 
the strip under general practice conditions.31,35
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The aim of this study was to assess the feasibility of 
screening a large diabetic population for microalbumin­
uria by means of the Micra) test in a general practice 
setting. This study compares measuring albumin concen­
tration in first morning urine on three consecutive days 
by means oftheMicrai test and by immuno-nephelometry.
Patients and Methods
Patients and Study Design
First morning urine samples on three consecutive days 
of 401 Type 2 diabetic patients were tested for micro­
albuminuria by means of the Micral test and by immuno- 
nephelometry. The immuno-nephelometric results served 
as reference values.
Patients were selected from the Nijmegen Monitoring 
Project (NMP).36 This is a longitudinal registration aimed 
at studying the course of Type 2 diabetes' mellitus and 
other chronic diseases in general practice. Since 1985 
all Type 2 diabetic patients in 10 general practices, 
including those who are under specialist medical care, 
have been included in this registration if the diagnostic 
evidence is in agreement with the WHO criteria.37 
Patients who were treated with insulin within 1 year of 
diagnosis and who remained on it were regarded as 
Type 1 diabetic patients. Ail other patients were regarded 
as Type 2, irrespective of their current treatment. 
Monitoring consists of the follow-up of the level of 
metabolic control, diabetes-related complications, cardio­
vascular morbidity, cardiovascular risk factors, and mor­
tality.
For this study all Type 2 diabetic patients in the 
Nijmegen Monitoring Project under control of their 
general practitioner were invited to participate in the 
screening for microalbuminuria. The screening took place 
at their routine diabetes check-ups over a period of 1 
year. All patients were asked to:
1. collect first morning urine samples on three consecu­
tive days;
2. store these samples at 4 °C (as this preserves the 
albumin concentration for up to 2 weeks38);
3. bring them to the practice on the morning of the 
third day.
All patients received instructions from the practice 
assistants and written explanation about the standardized 
procedures how to collect and store the urine samples. 
On the morning the patients brought their urine samples 
to the practice, these samples were first tested for nitrite 
and proteinuria by a dipstick test (N-combur test, 
Boehringer Mannheim, Germany). Samples with positive 
nitrite or albumin tests were excluded. All other samples 
were tested by the practice assistant by means of the 
Micral test. Aliquots of these samples were stored at
4 °C and analysed by immuno-nephelometry within 1 
week of collection.
Measurements o f Microalbuminuria
The Micral test is an immunochemical strip test specific 
for albumin. (Boehringer Mannheim, Germany) The 
reagent part of the test strip should be dipped into the 
urine for 5 s, then laid down horizontally and read after 
5 min. The intensity of the colour produced is proportional 
to the albumin concentration in the urine. The colour 
formed is compared with the reference chart on the vial. 
There are five colour blocks, reflecting categories of 
albumin concentrations of 0, 10, 20, 50, 100 mg I-1. 
Careful initial training was given to the general prac­
titioners (GPs) and practice assistants on the standardized 
procedures and performance of the Micral test. As 
reference values, albumin concentrations were also 
measured with the Disc 120 immuno-nephelometer 
(Hyland, Nivelles, Belgium) with an anti-serum raised in 
New Zealand white rabbits. Details of the immunization 
procedure and the immunological nephelometric method 
were published earlier.38 The coefficient of variation 
between batches was 3 % and 10 % in high concentration 
(mean 70.1 SD 2.1) and low concentration (mean 5.3, 
SD 0.6), respectively. The coefficient of variation within 
batches was 1.8 %. The detection limit was 1 mg I“ 1.
Analysis
The day-to-day variation of the albumin concentrations 
of each patient was calculated by assessing the agreement 
between the albumin concentration on first, second, and 
third mornings measured by nephelometry (Bland-Altman 
plot).39 A cut-off point of ^  20 mg I-1 was used to 
differentiate subjects with microalbuminuria from subjects 
without microalbuminuria. The sensitivity, specificity, 
predictive values, and likelihood ratios of the Micral test 
were based on the Micral test results of the first morning 
urine sample and the albumin concentrations measured 
in the same sample by immuno-nephelometry. The 
likelihood assesses the diagnostic power of a test. It is 
the quotient of the chance to find a positive test result 
in a sick individual (nominator) and the chance of a 
positive test result in a healthy subject (denominator). 
For a test which does not discriminate between sick and 
healthy individuals the nominator and denominator are 
equal, resulting in a likelihood ratio of 1.0. Test 
discrimination is better when the likelihood ratio for a 
positive test result is greater than 1.0 and for a negative 
test result when approximating zero. We calculated the 
reliability of the Micral test to single out those patients 
without microalbuminuria, defined by the mean nephelo­
metry result for the 3 days.
A Receiver Operating Characteristic (ROC) curve was 
constructed by graphing the sensitivity on the y-axis 
against the false positive fraction (1-specificity) on the 
x-axis. The area under this curve gives a measure for 
the diagnostic power of a test. For a test which does 
not discriminate between sick and healthy people the 
resulting ROC curve coincides with the diagonal and
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fable 1. The clay-to-day variation of the urine albumin concentration as the 
mean differences from the mean on three consecutive days in the same patient
Level of albumin 
concentration*1
Sample 1 Sample 3
0-9.9 ( / 7  = 174) 
10-19.9 (n = 77) 
20-49.9 (n = 48) 
50-99.9 (n = 5) 
100-300 (n =  13)
0.02 (1.3) 
2.1 (6 .2) 
0.4 (9.6) 
-4 .9  (8.9) 
23.5 (71.2)
0.00 ( 1.2 ) 
-1 .5  (4.2) 
-0.6 (10.2) 
-9 .5  (5.9) 
-15,2 (62.8)
-0 .0 3  (1.4) 
-0 .5  (5.1) 
0.3 (10.8) 
11.5 (8.3) 
-8 .3  (44.9)
Results as mu M with standard deviation in parentheses.
"'Mean urine albumin concentration on 3 consecutive clays measured by nephelometry.
will have an Area Under the Curve (AUC) of 0.5. A 
perfect test w ill have an AUC of 1.0/*°
Results
A complete set of three consecutive first morning urine 
samples was collected from 401 Type 2 diabetic patients. 
Using the N-Combur-test, nitrite was found in one or 
more of the samples in 22 patients and albumin in 64 
patients. O f the' remaining 317 patients three urine 
samples were tested by the Micral test and imrnuno- 
nephelometry. The day-to-day variation of albumin 
concentrations in the same patient was assessed by the 
mean difference between the urine albumin concentration 
measured by nephelometry on first, second, and third 
morning and their mean (Table I), The day-to-day 
variation seems to increase with the level of micro­
albuminuria.
Sensitivity, specificity, predictive? values, and likelihood 
ratios are based on the first Micral test (Tables 2 and 3). 
It was reasonable to present only the result of the first 
morning sample of each patient as the other samples 
give the same information. A threshold of 20 mg I 1 gives 
optimal balance» between sensitivity and specificity. A 
threshold of It) mg I 1 gives a poor specificity (44%), a 
threshold of 50 mg I ( a poor sensitivity (31 %). If the 
categories t) and 10 are regarded as negative test results, 
the Micral test is a good instrument to identify subjects 
without microalbuminuria (specificity 93 %). The test
Table 2. Urine» albumin concentrations as a result of first Micral 
test and immunomephelometry (Hyland-Disc 120)
Mitral
category
Urine u>neontralion by nephelometry (m# 1' 9
< 20 20.0-49.9 50.0-99.9 >  100
0 107 5* 2* 0
10 1Î6 U> Î 1
20 r> 21 t 5
50 > 12 2 *>
100 i >* * 4 2
was less suitable for identifying patients with an albumin 
excretion >  20 mg I“ 1 (sensitivity 67 %).
We analysed the data under three conditions for micro­
albuminuria:
1 ,
)
Mean value of the three measurements for nephelo­
metry s: 20 mg M (Table 4),
Median value of the three measurements for nephelo­
metry 20 mg I“ 1.
3. Two out of three nephelometry results ^  20 mg
As results were virtually the same, we presented the 
mean values*
Microalbuminuria, defined as a mean albumin concen­
tration >  20 mg I'“1 by nephelometry for three consecutive 
first morning urine samples, was present in 66 patients 
(21 %). O f these 66 patients, 12 had a Micral test result 
>  20 mg I"1 in none of the samples; 54 had one positive 
result, 47 had two and 39 three. The first Micral test 
correctly picked out these patients with microalbuminuria 
in 70% of the cases and in 90 % those patients w ithout 
microalbuminuria (Table 4).
The diagnostic performance of the Micral test was 
further proved by a ROC curve (Figure 1), The AUC of 
the Micral test was 0.84 (95% Cl 0.78-0.90).
Discussion
Results as absolute numbers.
AAll samples Iront ] of the It) participating practices.
We found that in a general practice setting the Micral 
test has good specificity and moderate sensitivity at the 
cut-off point of a urine albumin concentration of 
20 mg I- ’ . The frequency o f false positive results (T- 
specificity) was 7 %, occurring in 8 % of the study 
population. Since the Micral test is a screening test and 
not a diagnostic test, this number of false positive results 
is acceptable. The sensitivity of the Micral test was lower 
in our study than in the clin ical setting."“ ’' 1' The frequency 
of false negative results (1 -sensitivity) was 33 %, occurring 
in 5 % of the study population. This means that the 
Micral test has limited value for identifying patients 
with microalbuminuria. In screening, a fairly high false 
negative rate is only acceptable if  at the next screening 
the missed cases are detected still at a pre-cltnical 
stage. Cooper found that the mean duration of the
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Table 3. Evaluation of the Micral test compared to immuno-nephelometry
(Hyland-Disc 120)
Screening cut-off Sensitivity Specificity PV+a PV-b LR+C LR-d 
point (mg I ' 1)
>: 20 67 93 74 90 9.6 0.35
Results of sensitivity, specificity, and predictive values as percentages. 
aPredictive value of a positive test result. 
bPredictive value of a negative test result. 
cLikelihood ratio of a positive test result.
^Likelihood ratio of a negative test result.
Table 4. Reliability of the Micral test to identify patients 
with microalbuminuria defined as a mean urine albumin 
concentration >  20 mg I"1 in three consecutive first 
morning urine samples measured by nephelometry
Micral test3 Microalbuminuria (mean ^  20 mg I ] )
based on nephelometry13
Positive Negative
Positivec 45 24
Negative 20 228
“Micral test result of the first urine sample. 
bMean based on three nephelometry results.
'Positive is defined as a result in the category 20, 50 or 100.
1 0 0
80
S “ 60 ©"*
>%
P > 
ft 4 M A
'inc:
w 40
20
0
0 20 40 60 80 100
1 -  Specificity (% false positives}
Figure 1. Receiver Operating Characteristic (ROC) curve of 
the Micral test in general practice (n = 317). The AUC of the 
Micral test was 0.84 (95% Cl 0.78-0.90)
microalbuminuric phase was 3 to 4 years, with consider­
able individual variation.41 So the use of the Micral 
test can be supported if repeated measurements are 
performed. These repeated measurements probably ident­
ify patients with progression of proteinuria. According 
to our results 75 % of the patients with microalbuminuria 
were classified correctly by two out of three Micral tests 
(false negative 25 %). The AUC of the ROC curve (0.84) 
of the Micral test indicates good discrimination between 
patients with and without microalbuminuria using a cut­
off point of 5: 20 mg I-1.
There were some differences between the 10 general 
practices. In one practice (n = 66) the sensitivity of the 
Micral test was 58 % and the specificity 87 %. In another 
practice (n = 59) a sensitivity of 81 % and a specificity 
of 95 % was found. The range in sensitivity emphasizes 
how difficult it is to correctly perform a Micral test in a 
general practice setting. Poulsen evaluated the Micral 
test in three settings:
1. trained nurses,
2. laboratory technicians,
3. general practice.
The specificity of the Micral test was high (85-97 %) in 
all settings. However he found a decrease in sensitivity 
from almost 90% in laboratory technicians to 66%  in 
the general practice setting.35 Jury showed that the depth 
of dipping the strip into the urine sample and the time 
of reading the colour were critical.31 Marshall studied 
the time dependency of the test by comparing the results 
obtained for strips that were in contact with urine for 2 
and 5 s and by reading at 4, 5 and 6 min. Contact with 
urine for 2 s rather than the recommended 5 s resulted 
in an underestimation of the urine albumin concentration, 
as did taking readings earlier than the recommended 
5 min.29 This time dependency is a serious problem in 
general practice as the practice assistant has to perform 
diagnostic tests during other activities, such as telephone 
calls and patient contacts. Tiu demonstrated a consider­
able inter-observer variation in the matching of colours 
for the Micral test.28
These, as well as our results, clearly demonstrate the 
necessity of careful initial training, follow-up training, and 
a quality-control system to ensure continuing satisfactory 
performance of the Micral test. A limitation of the Micral 
test, as of all methods that measure urine albumin 
concentration, is the influence of diuresis. The wide day- 
to-day variations of diuresis and urine albumin excretion 
make it necessary to confirm an abnormal albumin
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concentration in first morning urine with a second test. 
In order to confirm diagnosis repeated abnormal results 
require ideally a timed urine collection. However, the 
correct collection of timed samples, even if the patient 
knows that he or she is at risk for nephropathy, may be 
very difficult. The measurement of albumin/creatinine 
ratios may be more reliable.
Based on the screening strategy proposed by the St 
Vincent declaration' and our findings, for general practice 
we suggest the screening strategy outlined in Figure 2. 
Patients with a Micral test result of 0 are highly unlikely 
to have a urinary albumin concentration ^  20 mg l~\ so 
these patients only need to be re-screened after 1 year. 
Approximately 40 % of the Type 2 diabetic patients in 
our study had a Micral test result of 10 mg I-1. Nearly 
20% of them had an albumin concentration ^  20 mg 
It seems sensible to perform another Micral test in those 
patients w ithin 4 weeks, if the second Micral test result 
falls into the category s  20 mg I ■' further diagnosis is 
required. In all other cases re-screening after 1 year
- 1
seems
Micral test results of 20, 50 or 100 mg I '1 are clearly 
found almost exclusively in those patients with an 
albumin concentration s; 20 mg I"1. In those cases we 
propose a second Micral test within 4 weeks, If the 
second Micral test result falls into the category £  20 mg I ' 1 
further diagnosis is required. In all other cases re- 
screening after 1 year seems justified.
We compared two screening strategies in terms of 
cost effectiveness. Both are based on albumin concen­
trations in first morning urine samples and using an
ORIGINAL ARTICLES
albumin concentration threshold of 20 mg - 1 Strategy
1: screening using nephelometry and Strategy 2: screening 
using Micral test. The cost of the nephelometry assay 
was £10.40 and that of the dipstick £1.28, based on the 
Dutch real costs (assay-dipstick cost ratio 8.1). The cost- 
effectiveness of this screening strategy was calculated in 
a fictitious cohort o f 100 diabetic patients.
Strategy 1: all patients screened with nephelometry. The 
costs include a first test for all patients and a second 
test for patients with results on first screening ^  20 mg I-1 
(about 20% ): (100 + 20) x  10.40 = £1248 (exclusive of 
costs due to the storage and the transport at 4 °C of the 
urine samples from the practice to the laboratory). 
Strategy 2: all patients screened with Micral test. The 
costs include a first dipstick for all patients and a second 
dipstick for patients w ith results on first screening 
(about 65 %): (100 + 65) x  1.28 = £211.20.
Floch studied the cost-effectiveness of screening for 
microalbuminuria using the Micral test or laboratory 
assay in a fictitious cohort of 10 000 diabetic patients 
(Types 1 and 2).;,:i He stated that the cost-effectiveness 
of the Micral test was strongly related to the frequency 
of false negative results. In that study the frequency of 
false negative results was 9.2% (the Micral test was 
performed in a clin ical setting); if increased to 15 -20%  
the effectiveness decreased dramatically. The frequency 
of false negative results in our study was even higher. 
Although the practice assistants and GPs received initial 
training, follow-up training and quality control might 
have contributed to a higher sensitivity.
0
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Figure 2. Screening strategy Micral test in general practice. Patients with a Micral test result of 0  are highly unlikely to have a 
urinary albumin concentration & 21) mg I so these patients only need to be re-screened after 1 year. In patients with a Micral 
lest result of 10 it is sensible to perform another Micral lest within 4 weeks. If the second Micral test result falls into the category 
20 a timed quantitative measurement is recommended. In all other cases re-screening after 1 year seems justified. In patients 
with Micral lest results of 20, fit) or 100 we propose a second Micral test within 4 weeks. If the second Micral test result falls 
again into the category ■- 20 a timed quantitative measurement is recommended. In all other cases re-screening after 1 year
seems justified
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Apart from the cost reduction in strategy 2 of almost 
85 %, the Micral test has the practical advantage that 
the result is immediately available during the patient's 
visit. Moreover, the urine samples do not have to be 
stored at 4 °C and sent to a laboratory.
In conclusion, screening for microalbuminuria in Type 
2 diabetic patients is still a controversial topic because 
it has to be proven whether interventions can delay the 
development of renal failure, cardiovascular morbidity, 
and mortality. However, there is growing evidence in 
favour of screening for microalbuminuria. As most Type
2 diabetic patients are treated in general practice such 
a screening should be easily applicable in that setting. 
Our results suggest that the use of the Micral test can 
only be supported if strict standardized procedures are 
followed and repeated measurements are performed.
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